About Xenon Pharmaceuticals (NASDAQ:XENE)
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300
Debt
Debt-to-Equity Ratio0.17%
Current Ratio10.98%
Quick Ratio10.99%
Price-To-Earnings
Trailing P/E Ratio-2.94
Forward P/E Ratio-3.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales230.83
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book2.53
Profitability
EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-65.72%
Return on Assets-59.20%
Miscellaneous
Employees81
Outstanding Shares14,170,000
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its quarterly earnings data on Wednesday, March, 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.34. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $6.38 million. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
3 analysts have issued 1 year target prices for Xenon Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $6.6667 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Acer Therapeutics (ACER), Zynerba Pharmaceuticals (ZYNE), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Galectin Therapeutics (GALT), Sierra Oncology (SRRA), Affimed (AFMD), Aeglea Bio Therapeutics (AGLE), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP), Checkpoint Therapeutics (CKPT), Bellerophon Therapeutics (BLPH), AcelRx Pharmaceuticals (ACRX), Axovant Sciences (AXON), ProQR Therapeutics (PRQR), OncoMed Pharmaceuticals (OMED), Trevena (TRVN) and Otonomy (OTIC).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Michael M. Tarnow, Chairman of the Board (Age 71)
- Ian C. Mortimer CPA, President, Chief Financial Officer, Chief Operating Officer (Age 42)
- Simon Neil Pimstone Ph.D., Chief Executive Officer, Director (Age 48)
- James R. Empfield, Senior Vice President - Drug Discovery
- Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development (Age 54)
- Charles M. Cohen Ph.D., Vice President - Biology (Age 66)
- Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development (Age 55)
- Karen G. Corraini J.D., General Counsel and Corporate Secretary (Age 60)
- Mohammad Azab, Director (Age 59)
- Steven R Gannon, Director (Age 55)
Has Xenon Pharmaceuticals been receiving favorable news coverage?
News articles about XENE stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $5.05.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $75.11 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Xenon Pharmaceuticals in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 32.01%. The high price target for XENE is $9.00 and the low price target for XENE is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.6667 | $6.6667 | $5.00 | $8.1667 |
| Price Target Upside: | 32.01% upside | 36.05% upside | 66.67% upside | 172.22% upside |
Xenon Pharmaceuticals (NASDAQ:XENE) Consensus Price Target History
Xenon Pharmaceuticals (NASDAQ:XENE) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Xenon Pharmaceuticals (NASDAQ:XENE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 64.62%
Xenon Pharmaceuticals (NASDAQ XENE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/15/2017 | Mohammad Azab | Director | Buy | 15,000 | $2.22 | $33,300.00 | |  |
| 9/22/2017 | Mohammad Azab | Director | Buy | 10,000 | $2.95 | $29,500.00 | 21,210 | |
| 8/18/2017 | Mohammad Azab | Director | Buy | 6,335 | $2.90 | $18,371.50 | 12,898 | |
| 8/18/2017 | Raymond Winquist | Insider | Buy | 1,000 | $3.00 | $3,000.00 | 1,000 | |
| 8/15/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 18,858 | $2.41 | $45,447.78 | | |
| 8/15/2017 | James R Empfield | SVP | Buy | 10,000 | $2.48 | $24,800.00 | 10,000 | |
| 8/15/2017 | Value Fund L P Biotechnology | Insider | Buy | 60,202 | $2.61 | $157,127.22 | | |
| 8/14/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 41,344 | $2.70 | $111,628.80 | | |
| 8/14/2017 | Michael R Hayden | Director | Buy | 15,000 | $2.75 | $41,250.00 | 161,187 | |
| 8/11/2017 | Steven Gannon | Director | Buy | 15,000 | $2.82 | $42,300.00 | 15,000 | |
| 8/10/2017 | Ian Mortimer | CFO | Buy | 15,000 | $2.88 | $43,200.00 | 6,000 | |
| 8/10/2017 | Richard H Scheller | Director | Buy | 7,000 | $2.85 | $19,950.00 | 7,000 | |
| 8/10/2017 | Simon N Pimstone | CEO | Buy | 6,000 | $2.90 | $17,400.00 | 217,847 | |
| 8/8/2017 | Gary Patou | Director | Buy | 5,000 | $3.00 | $15,000.00 | 12,028 | |
| 6/27/2017 | Value Fund L P Biotechnology | Insider | Buy | 85,461 | $4.00 | $341,844.00 | | |
| 6/22/2017 | Value Fund L P Biotechnology | Insider | Buy | 20,411 | $4.00 | $81,644.00 | | |
| 6/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 26,408 | $3.84 | $101,406.72 | | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 358,698 | $3.81 | $1,366,639.38 | | |
| 12/15/2016 | Frank A Holler | Director | Sell | 30,000 | $7.85 | $235,500.00 | 115,869 | |
| 8/19/2016 | Frank A Holler | Director | Sell | 11,938 | $7.65 | $91,325.70 | 145,869 | |
| 8/18/2016 | Frank A Holler | Director | Sell | 18,062 | $7.93 | $143,231.66 | 169,006 | |
| 6/24/2016 | Ian Mortimer | CFO | Buy | 5,300 | $6.22 | $32,966.00 | 1,000 | |
| 9/24/2015 | Y. Paul Goldberg | VP | Sell | 22,149 | $8.88 | $196,683.12 | 6,000 | |
(Data available from 1/1/2013 forward)
Xenon Pharmaceuticals (NASDAQ XENE) News Headlines
| Source: |
|
Xenon Pharmaceuticals (NASDAQ:XENE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Xenon Pharmaceuticals (NASDAQ:XENE) Income Statement, Balance Sheet and Cash Flow Statement
Xenon Pharmaceuticals (NASDAQ XENE) Stock Chart for Sunday, April, 22, 2018
Loading chart…
